Online citations, reference lists, and bibliographies.

Proton Pump Inhibitors, Osteoporosis, And Osteoporosis-related Fractures.

Marc R Fournier, L. Targownik, W. Leslie
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Proton pump inhibitors (PPIs) are among the most commonly prescribed medications today with an excellent short-term safety profile. Recently, a number of studies from a variety of data sources have reported an association between PPI use and hip fractures. However, there is not yet any direct evidence of a causal link between PPI use and the development of hip fracture. In the following paper, we will review the recent studies which have described this association between PPI use and hip fracture, and discuss the evidence supporting the likelihood of this association being causal, using data from previous work on the effects of surgical and pharmacological inhibition of gastric acid secretion on calcium absorption and bone mineral density. We will conclude by summarizing the current state of evidence on the relationship between gastric acid inhibition and the risk of fracture, and suggest management strategies for patients who require the long-term use of gastric acid inhibiting medications who also may be at risk for metabolic bone disease and fracture.
This paper references
10.2174/157488608785699414
Proton pump inhibitor therapy and osteoporosis.
Yu-Xiao Yang (2008)
10.1001/jama.1996.03540120061035
Gastroesophageal reflux disease.
P. Kahrilas (1996)
10.7326/0003-4819-132-5-200003070-00003
Low Fractional Calcium Absorption Increases the Risk for Hip Fracture in Women with Low Calcium Intake
K. Ensrud (2000)
10.1592/phco.28.8.951
Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
J. Kaye (2008)
10.1007/BF01352010
Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans
K. Mizunashi (2005)
10.1016/S0016-5085(09)60316-4
414 Proton Pump Inhibitors, H2 Antagonists, and Risk of Hip Fracture: A Large Population-Based Study
Douglas A. Corley (2009)
10.1007/BF01556392
Effects of gastric resection and vagotomy on blood and bone mineral content
M. Blichert-Toft (1979)
10.1093/ajcn/43.2.299
Distribution of calcium absorption in middle-aged women.
R. Heaney (1986)
10.1001/JAMA.294.23.2989
Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile–Associated Disease
S. Dial (2005)
10.1093/NDT/14.8.1922
Risk factors for reduced bone density in haemodialysis patients.
M. Taal (1999)
10.1016/0169-6009(90)90059-O
Partial gastrectomy and mineral metabolism: effects on gastrin-calcitonin release.
P. Filipponi (1990)
10.1007/s00223-008-9188-4
Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole
C. Roux (2008)
10.1056/NEJM198507113130202
Calcium absorption and achlorhydria.
R. Recker (1985)
10.1001/JAMA.298.20.2381
High-trauma fractures and low bone mineral density in older women and men.
D. Mackey (2007)
10.1056/NEJM199803123381104
A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group.
N. Yeomans (1998)
10.1172/JCI111254
An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium.
G. Bo-Linn (1984)
10.1172/JCI111373
Impaired vitamin D metabolism with aging in women. Possible role in pathogenesis of senile osteoporosis.
K. S. Tsai (1984)
10.1172/JCI109516
Intestinal calcium absorption and serum vitamin D metabolites in normal subjects and osteoporotic patients: effect of age and dietary calcium.
J. Gallagher (1979)
10.1093/ajcn/80.6.1689S
Overview of general physiologic features and functions of vitamin D.
H. DeLuca (2004)
10.1503/cmaj.071330
Use of proton pump inhibitors and risk of osteoporosis-related fractures
L. Targownik (2008)
10.1007/BF02556841
Omeprazole, a specific inhibitor of H+−K+-ATPase, inhibits bone resorptionin vitro
J. Tuukkanen (2007)
Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group.
K. Ensrud (2000)
10.1002/14651858.cd002095.pub2
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
B. van Pinxteren (2006)
10.1111/j.1572-0241.2007.01106.x
The Prevalence of and the Clinical and Demographic Characteristics Associated With High-Intensity Proton Pump Inhibitor Use
L. Targownik (2007)
10.1097/00132579-200302000-00001
Step-down management of gastroesophageal reflux disease.
J. Inadomi (2001)
10.1053/j.gastro.2008.08.044
American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease.
P. Kahrilas (2008)
10.1002/14651858.CD002095.PUB5
Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
B. van Pinxteren (2004)
10.1007/BF02557827
Influence of PTH and 1,25(OH)2D on calcium homeostasis and bone mineral content after gastric surgery
L. Nilas (1985)
10.1080/07315724.1995.10718522
Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans.
C. Serfaty-Lacrosniere (1995)
10.1007/s002239900431
Bone Mineral Density in Patients Taking H2-Receptor Antagonist
Y. Adachi (1998)
10.1053/GAST.2003.50106
AGA technical review on osteoporosis in gastrointestinal diseases.
Charles N. Bernstein (2003)
10.1056/NEJM198812293192605
The physiology of gastric acid secretion.
M. Wolfe (1988)
10.1007/s00223-006-0021-7
Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture
P. Vestergaard (2006)
10.1038/ajg.2009.48
Proton Pump Inhibitors and Bone Fractures?
L. Laine (2009)
10.1001/JAMA.292.16.1955
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
R. Laheij (2004)
10.1001/JAMA.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1210/JC.2006-1415
Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice.
W. Leslie (2007)
10.1016/S0140-6736(78)91141-8
CALCIUM BINDING BY DIETARY FIBRE
W. P. James (1978)
10.7326/0003-4819-66-5-917
The absorption of calcium carbonate.
P. Ivanovich (1967)
10.1038/ajg.2009.44
The Effect of Proton Pump-Inhibiting Drugs on Mineral Metabolism
K. Insogna (2009)
10.1001/ARCHINTE.160.12.1810
Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.
J. Richter (2000)
10.1007/s00223-008-9170-1
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
E. Yu (2008)
10.1136/bmj.1.6072.1310
25-Hydroxycholecalciferol absorption in steatorrhoea and postgastrectomy osteomalacia.
J. Gertner (1977)
10.1016/J.AMJMED.2005.02.007
Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial.
M. B. O'Connell (2005)



This paper is referenced by
10.1016/j.jor.2016.01.002
In vitro comparative assessment of the mechanical properties of PMMA cement and a GPC cement for vertebroplasty.
Omar Ali Abouazza (2016)
10.4292/wjgpt.v2.i3.17
Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?
Alexander L Fohl (2011)
10.1254/JPHS.09355FP
Effect of an herbal preparation, STW 5, in an acute model of reflux oesophagitis in rats.
Heba Abdel-Aziz (2010)
10.1016/j.clinbiochem.2012.01.024
Laboratory testing for secondary osteoporosis evaluation.
Robert A. Adler (2012)
10.3999/JSCPT.42.369
3. 消化器内科の立場から(PPI併用慎重派) ―PPI長期投与の問題点―
宏 安田 (2011)
10.2165/11536780-000000000-00000
Proton Pump Inhibitors and Fracture Risk
M. Bodmer (2010)
10.12816/0033776
Risk of Osteoporosis and Osteopenia in Patients with Prolonged Use of Proton Pump Inhibitors
Abdullah Ali Al-Zahrany (2016)
10.1002/9781118662915.CH19
Complications of drugs used in gastroenterology
Paul K. Hamilton (2016)
10.1111/jvp.12371
Pharmacokinetics and tolerability of a new formulation of omeprazole in the horse
A Di Salvo (2017)
10.1007/s40261-017-0519-y
Acid-Suppressive Therapy and Risk of Infections: Pros and Cons
L. Fisher (2017)
10.1016/j.bone.2020.115306
Comparative analysis of the risk of osteoporotic fractures with proton pump inhibitor use and histamine-2 receptor antagonist therapy in elderly women: A nationwide population-based nested case-control study.
J. Park (2020)
10.1016/j.ydbio.2015.08.014
H(+)/K(+) ATPase activity is required for biomineralization in sea urchin embryos.
Daphne Schatzberg (2015)
10.1007/978-1-4419-5792-4_25
Osteoporosis and Metabolic Bone Diseases of the Elderly
Lora M. Giangregorio (2011)
10.1016/J.JEVS.2015.07.003
Short-Term Omeprazole Use Does Not Affect Serum Calcium Concentrations and Bone Density in Horses
S S Caston (2015)
The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong.
T. Ip (2013)
10.3389/fnut.2020.00037
Nutrigenomics-Associated Impacts of Nutrients on Genes and Enzymes With Special Consideration of Aromatase
H. Jenzer (2020)
10.1016/B978-0-12-415784-2.00006-3
Gastrointestinal Tract and the Control of Bone Mass
Thorsten Schinke (2013)
The Evaluation of omeprazole effect on the sensitivity of 99mTc-MDP bone-seeking to detect simulated closed fracture in the rat’s foot
A. Doroudi (2017)
10.1016/j.nut.2012.07.014
Can 2-oxoglutarate prevent changes in bone evoked by omeprazole?
Piotr Dobrowolski (2013)
10.1097/MOG.0b013e328340a7b4
Current World Literature
(2010)
10.1016/S1734-1140(12)70858-7
Proton pump (H+/K+-ATPase) inhibitors weaken the protective effect of alendronate on bone mechanical properties in estrogen-deficient rats.
Maria Pytlik (2012)
The Role of Sorting Nexin 10 (Snx10) in Control of Osteoclast Function and Regulation of Bone Homeostasis
Liang Ye (2014)
10.11005/jbm.2018.25.3.141
Proton-pump Inhibitor Use and Fracture Risk: An Updated Systematic Review and Meta-analysis
Y. Nassar (2018)
10.1016/j.bone.2010.05.019
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.
A. Giusti (2010)
10.4172/2161-0509.1000191
Know-how and Know-why Nutrients may be Less Bioaccessible and Less Bioavailable due to Proton Pump Inhibitor - Food Interactions and Incompatibilities Involving Metal-Aquo Complexes
H. Jenzer (2016)
Implicaciones de la utilización de las guías de mayor impacto internacional (NOGG y NOF) como de otras guías (internacionales, nacionales y locales) en la eficiencia diagnóstica y terapéutica de la osteoporosis en el Área de Salud de León
G. Kyriakos (2016)
10.1177/1753465810392264
A new strategy with proton pump inhibitors for the prevention of acute exacerbations in COPD
T. Sasaki (2011)
Long term use of proton pump inhibitors : is there an increase in fracture risk?
Rachel Renee Mutchler (2010)
10.2165/11596000-000000000-00000
Targeting Outpatient Drug Safety
M. W. Herwaarden (2012)
10.1016/j.ctcp.2015.09.005
Effects of Quince syrup on clinical symptoms of children with symptomatic gastroesophageal reflux disease: A double-blind randomized controlled clinical trial.
Mohammad Ebrahim Zohalinezhad (2015)
10.1016/j.maturitas.2014.05.019
Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
L. Moberg (2014)
10.1016/j.rdc.2012.09.001
Safety of bisphosphonates.
C. Orozco (2012)
See more
Semantic Scholar Logo Some data provided by SemanticScholar